Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Arrowhead Pharma (NQ: ARWR )

21.87 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 21.87
Bid (Size) 21.00 (1)
Ask (Size) 23.79 (1)
Prev. Close 21.87
Today's Range 21.87 - 21.87
52wk Range 20.67 - 42.48
Shares Outstanding 105,736,200
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Second Quarter Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire

Performance

YTD
-29.47%
-29.47%
1 Month
-21.44%
-21.44%
3 Month
-34.56%
-34.56%
6 Month
-10.37%
-10.37%
1 Year
-38.43%
-38.43%

More News

Read More
Turnstone Biologics Appoints William Waddill to its Board of Directors
From Turnstone Biologics Corp.
Via GlobeNewswire
Cracking The Code: Understanding Analyst Reviews For Arrowhead Pharma
Via Benzinga
Recap: Arrowhead Pharma Q1 Earnings
Via Benzinga
Earnings Scheduled For February 6, 2024
Via Benzinga
Arrowhead Pharmaceuticals Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
The 7 Most Undervalued Russell 2000 Stocks to Buy in April 2024
Via InvestorPlace
NetApp, Zoom Video And 2 Other Stocks Insiders Are Selling
Via Benzinga
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals Initiates Expanded Access Program for Plozasiran and Announces Upcoming Presentation of Clinical Data
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
7 Biotech Stocks to Buy as Sector Rotation Ramps Up
Via InvestorPlace
The 3 Most Undervalued Russell 2000 Stocks to Buy in March 2024
Via InvestorPlace
EQT, Genie Energy And Other Big Stocks Moving Lower On Monday
Via Benzinga
Topics Stocks
Exposures US Equities
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals to Participate in Upcoming March 2024 Conferences
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday
Via Benzinga
Topics Stocks
Exposures US Equities
7 Oversold Russell 2000 Stocks to Add to Your February Buy List
Via InvestorPlace
Weight-Loss Drugs Have One Big Problem. These Drugmakers Are Taking It On.
Via Investor's Business Daily
7 Biotech Stocks Fighting America’s Deadliest Diseases
Via InvestorPlace
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Arrowhead Pharmaceuticals Reports Fiscal 2024 First Quarter Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals to Webcast Fiscal 2024 First Quarter Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals Closes Underwritten Offering with Gross Proceeds of $450.0 Million
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
Via Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.